Introduction
Tumor metastasis is a major cause of mortality in patients with pancreatic cancer (1) . It has been shown that deregulation of cell proliferation and anti-apoptosis can lead to tumor initiation, progression or metastasis. Compelling evidence indicates that the deregulation of several signaling molecules is associated with progression of pancreatic cancer (2) . Of these signaling molecules, the non-receptor-tyrosine kinase, c-Src, is overexpressed in 70% of human pancreatic cancers and its activity is an important property of tumor progression (3) .
Src family kinases (SFKs) transmit signals between cell surface proteins and other intracellular proteins (4) (5) (6) . Recent studies suggest that the activity of Src may also modulate cell apoptosis and influence tumor progression (7) . Fyn, a critical member of the SFK family, mediates a variety of cellular processes, including T-cell receptor signaling (8) , regulation of brain function (9) and adhesion-mediated signaling (10) . Our previous study showed that activation of Fyn promotes cell proliferation and metastasis in pancreatic cancer (11) . However, the role of Fyn in apoptosis regulation is unknown.
Alternative splicing is known to play a role in apoptosis. A clear example of this is the Bcl-x transcript, which has two alternatively spliced products; the anti-apoptotic Bcl-x(L) and the pro-apoptotic Bcl-x(s) (12) . Cancer cells often alter Bcl-x splicing to escape from apoptosis, which results in tumor formation, metastasis and a poor prognosis for the patient (13) . Recent reports have shown that the RNAbinding protein Sam68 binds to Bcl-x messenger RNA (mRNA), which affects its alternative splicing (14) . The role of Sam68 in Bcl-x splicing is regulated by phosphorylation (15, 16) . In normal cells, the unphosphorylated Sam68 is predominantly localized in the nucleus, where it participates in Bcl-x pre-mRNA processing. However, in cancer cells, the highly phosphorylated Sam68 is distributed in the cytoplasm and leads to a decrease in the regulation of Bcl-x splicing (17) . The participation of other RNA-binding proteins in regulating the alternative splicing of Bcl-x and the resulting in cancer metastasis is unknown.
As a group of RNA-binding proteins, heterogenous nuclear ribonucleoproteins (HnRNPs) regulate the splicing and transportation ofmRNA and participate in growth regulation and carcinogenesis (18) . The increased expression of HnRNPA2B1 has been detected in both lung cancer and pancreatic cancer and is thought to be involved in cancer progression (19, 20) . However, the mechanism by which HnRNPA2B1 promotes tumor metastasis is not clear. Our preliminary study showed that the activity of Fyn and the expression of HnRNPA2B1 were significantly increased in human metastatic pancreatic cancers. To determine whether Fyn promotes metastasis by regulating cell apoptosis via HnRNPA2B1, we evaluated the relationship between the metastasis of pancreatic cancer, the activity of Fyn and expression of HnRNPA2B1 in human pancreatic cancer tissues. We then investigated how the mechanism of apoptosis was regulated by the Fyn-HnRNPA2B1/Sam68-signaling pathway in pancreatic cancer using multiple experimental approaches.
Materials and methods

Cell lines and antibodies
Human pancreatic cancer cell lines, including BxPc3, AsPc1 and PaCa2, were purchased from the Shanghai Biomedical Institute and cultured in Dulbecco's modified Eagle's mediu with 10% fetal bovine serum. Antibodies, including anti-Fyn, anti-HnRNPA2B1 (Sigma-Aldrich, St Louis, MO); anti-Sam68, anti-HnRNPA1 (Santa Cruz Biotechnology, Santa Cruz, CA); anti-Src (Cell Signaling, Danvers, MA); PY-Plus anti-phosphotyrosine (Zymed, South San Francisco, CA) and anti-GAPDH (Abcam, San Francisco, CA) were purchased from the Shanghai Biological Incorporation (Shanghai, China).
Tissue samples A total of 28 pancreatic cancer patients from our institute were involved in this study. The tumor specimens included 11 metastatic pancreatic cancer (liver metastasis) specimens and 17 non-metastatic pancreatic cancers, in addition to pancreatic tissues that were adjacent to cancer cells. These were obtained from surgery, instantly fixed in formalin and then embedded in paraffin. Each pancreatic cancer specimen was reviewed by two pathologists. The research protocol was approved by the Institutional Review Board and all patients gave their informed consent prior to their inclusion.
Expression of adenovirus-mediated HnRNPA2B1 and KD-Fyn
The complementary DNAs of kinase-dead Fyn (KD-Fyn), constitutive-active Fyn (CA-Fyn) and constitutive-active Src (CA-Src) were generously offered by Dr H.Kawakatsu (University of California in San Francisco, USA). The full length of the HnRNPA2B1 coding sequence was obtained using a PrimeScript RT-PCR Kit (Takara Biotechnology (Dalian) Co., Ltd., DaLian, Province of Liaoning, China) and from HEK293 RNA according to the manufacturer's instructions. The PCR products were identified by sequencing.
Abbreviations: ATP, adenosine triphosphate; HnRNP, heterogenous nuclear ribonucleoprotein; KD-Fyn, kinase-dead Fyn; RNAi, RNA interference; RT-PCR, reverse transcription-polymerase chain reaction; SFK, Src family kinase. 
RNA interference
The selected shRNA sequence to target HnRNPA2B1 mRNA strands was 5#-CGTGCTGTAGCAAGAGAGG-3#. BLAST alignment showed no sequence identity with other transcripts of human genes. An oligonucleotide (5#-CGTACGCGGAATACTTCGA-3#) targeting firefly luciferase mRNA was used as a negative control. The synthesized oligonucleotides were annealed and inserted into pGenesil-3 plasmids by following established protocols.
The adenoviruses that expressed HnRNPA2B1-shRNA and the control small interfering RNA were constructed using the AdEasy Vector System (Stratagene), according to the manufacturer's instructions. For adenovirus infection, BxPC3 cells were infected with the desired dose of adenovirus on a 21 cm 2 plate. Transfections were performed for two or three consecutive days. The efficacy of gene silencing was assessed by immunoblot analysis.
Immunohistochemical staining
The deparaffinized sections were trypsinized (0.05% trypsin with 0.05% Triton X-100 in tris-buffered saline) for 20 min and blocked with 10% goat serum in Superblock. Each section was incubated separately with the antibodies at 4°C overnight, and the slides were then processed in the Ventana-automated stainer, according to the instructions of the manufacturer. The immunoperoxidase-3, 3-diaminobenzidine-stained slides were subsequently counterstained with hematoxylin and mounted with a coverslip. Adjacent pancreatic tissues were used as the control.
Two-dimensional Difference Gel Electrophoresis
The proteins were extracted from pancreatic cancer cells using a Bio-Rad protein extraction kit (Bio-Rad Laboratories, Hercules, CA). Protein samples ($250 mg) were incubated with 5 ml Buffer II (50 mM MgCl 2 , 10 U DNase I, 3.73 U RNase, 50 mM Tris-HCl) on ice for 10 min and resolved in 350 ml IPG buffer (7 M urea, 2% CHAPS (wt/vol), 0.5% IPG buffer). The sample solution was immobilized on pH 3-10 nonlinear gradient strips using IPGphor. The first dimension was performed using three steps: 500 vol for 1 h, 1000 vol for 1 h and 8000 vol for 8 h. The second dimension was run on a 10% polyacrylamide sodium dodecyl sulfate gel using a PROTEAN II xi electrophoresis kit (Bio-Rad Laboratories). Silver staining was then carried out. Image acquisition was obtained by an Amersham Pharmacia Biotech (Piscataway, NJ, USA) image scanner and 2D image analysis was performed by Phoretix 2D Evolution Software. Normalized volumes of protein spots on the 2D gel images of succinate and aniline-cultured cells were analyzed for quantitative comparison.
Direct Fyn kinase assays
The proteins were extracted from pancreatic cancer tissues using a Bio-Rad protein extraction kit. Fyn proteins were immunoprecipitated by incubating the primary antibodies and the direct Fyn kinase assays in accordance with the instructions provided by Upstate Biotechnology (Lake Placid, NY). In brief, every reaction contained 6.25 ll of assay buffer [200 mM Tris-HCl (pH 7.5), 0.4 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid and 0.4 mM sodium orthovanadate] and a magnesium acetate-adenosine triphosphate (ATP) Fyn-HnRNPA2B1/Sam68 and pancreatic cancer cocktail buffer [2.5 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid (pH 7.4), 50 mM magnesium acetate and 0.5 mM ATP]. For Fyn kinase, the Src substrate peptide was included at 250 lM. Ten nanograms of Fyn protein and 10 ll of diluted [c-32 P]ATP solution were incubated at 30°C for 10 min with the above assay buffer and substrate peptide, then 15 ll aliquots were transferred onto p81 paper and washed three times with 0.75% phosphoric acid for 5 min, then once with acetone for 5 min. The radioactive incorporation was determined using a scintillation counter. The relative kinase activities are calculated as the ratio of SFKs radioactivity incorporated on the P81 paper to the radioactivity of 10 ll of diluted [c-32 P]ATP. Each experiment was performed three times.
Immunoprecipitation, in vitro kinase assay and RNA-protein immunoprecipitation Immunoprecipitations were performed by incubating the primary antibodies with the cell lysates for 2 h or overnight at 4°C. The immunocomplex was captured by adding protein A-agarose for 1 h at 4°C. The immunoprecipitates were analyzed by Western blotting or kinase assays.
In vitro autophosphorylation assays were performed as described previously (10) . Src and Fyn immunoprecipitates were washed once with kinase reaction buffer (20 mM PIPES, pH 7.4, 10 mM MnCl 2 ) and labeled for 30 min at 37°C by adding 0.5 ml of [c-32 P]ATP [3000 Ci/mmol (10 mCi/ml)]. The labeled protein, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was transferred to a nylon membrane and then exposed to x-ray film to detect incorporated radioactivity. The blotting was quantified using an Amersham Biosciences PhosphorImager.
For RNA-protein immunoprecipitations, 500 lg of extracted proteins were precleared with 20 ml protein A/G Plus agarose and then incubated with 2 lg of anti-HnRNPA2B1 overnight at 4°C at constant rotation. The coprecipitated RNA was then extracted by phenol/chloroform and used for further analysis.
Reverse transcription-polymerase chain reaction analysis Either 0.5 lg of RNA from cells or coimmunoprecipitated RNA was used for reverse transcription-polymerase chain reaction (RT-PCR) using a PrimeScript RT-PCR Kit according to the manufacturer's instructions. The primers used were shown in Table S1 (supplementary Table S1 is available at Carcinogenesis Online). The PCR products were analyzed by 2% agarose gel and visualized under ultraviolet light. Quantity One V4.40 software was used to quantify the densitometry of visualized bands and calculate the relative value units of densitometry.
Cell apoptosis assay
After cells were cultured under serum-free conditions for 24 h, cell apoptosis was determined using an in situ cell death detection kit (Roche Diagnostics, Mannheim, Germany) and then analyzed by an Olympus BX-40 microscope equipped with a CCD camera. The results were expressed as a percentage of the total cells.
Statistical analysis
Statistical analysis was performed using SPSS software for Windows version 10.0 (SPSS, Chicago, IL). Correlation analysis was conducted using Pearson's test. P , 0.05 was considered to be a statistically significant difference.
Results
The activity of Fyn is increased in metastatic pancreatic cancers Our previous study showed that, in pancreatic cancer tissues, the expression of Fyn was correlated with metastasis of human pancreatic cancers (11) . We further analyzed the activity of Fyn and Src in 10 metastatic pancreatic cancers, 10 non-metastatic pancreatic cancers and 5 samples of the pancreas taken from tissue adjacent to cancers. As shown in Figure 1A , the activities of Fyn were significantly increased, but the activities of Src were only slightly increased in the metastatic pancreatic cancer tissues in comparison with the nonmetastatic pancreatic cancer tissues.
We next analyzed the activities of Src and Fyn in pancreatic cancer cell lines, including those with a highly metastatic potential (BxPc3), a slightly metastatic potential (AsPc1) and a non-metastatic potential (PaCa2). The cell lysate was immunoprecipitated with anti-Src and anti-Fyn then subjected to an in vitro kinase assay to determine the activity of SFKs. We found that the incorporation of 32 P into Fyn was the highest in BxPc3 cells, moderate in AsPc1 cells and the lowest in Paca2 cells ( Figure 1B top panel, lanes 1 and 2 versus 3) . In contrast, 32 P incorporation into Src ( Figure 1C top panel) was equivalent in these pancreatic cancer cells. Equivalent levels of these two proteins were expressed in the pancreatic cancer cells ( Figure 1B and C, bottom panels). These results indicate that Fyn activity is increased in the highly metastatic pancreatic cancer cells.
Fyn activity regulates HnRNPA2B1 expression in pancreatic cancers
To characterize the expression profiles and identify protein species associated with Fyn activity, we transfected KD-Fyn into BxPc3 cells and performed a proteomic analysis using 2D gel. As shown in Figure  2A , Fyn expression increased but Fyn activity decreased in BxPc3KD-Fyn cells. The 2D gel images of the cellular proteins are shown in Figure 2B . Using a statistical analysis of protein spot signals (the Decyder program), 346 spots were found to be differentially expressed between treated and untreated samples. Among these, 12 protein species were successfully identified by matrix assisted laser desorption ionization/time of flight MS analysis. Of the identified proteins, HnRNPA2B1, a protein related to RNA processing, was significantly downregulated by KD-Fyn ( Figure 2B and supplementary Table S2 is available at Carcinogenesis Online).
To prove whether Fyn activity regulates HnRNPA2/B1 expression, we evaluated HnRNPA2B1 expression with a western blot analysis of extracts of BxPc3 cells, BxPc3KD-Fyn cells and SYF cells (Fyn-and Src-knockout fibroblasts). As shown in Figure 2C We detected HnRNPA2B1 expression in 28 cases of pancreatic cancer using immunohistochemistry. As shown in Figure 2E , HnRNPA2B1 expression was significantly increased and mainly distributed in the cell nucleus of the metastatic pancreatic cancer cells. Statistical analyses showed that HnRNPA2B1 expression was associated with T: primary tumour, N: regional lymphnodes, M: distant metastasis (TNM) stage (P 5 0.001, R 5 0.854) and metastasis (P 5 0.002, R 5 0.698) ( Table I) . Table I HnRNPA2B1 is a key splicing factor for Bcl-x(s) in pancreatic cancer cells HnRNPA2B1 is an RNA-binding protein that regulates cell proliferation (18) . To determine whether HnRNPA2B1 plays a direct role in the posttranscriptional modification of mRNAs of known apoptotic regulators such as the Bcl-family genes, an endogenous HnRNPA2B1/RNA complex was extracted from BxPc3 cells to analyze the presence of Bcl-family genes by RT-PCR as described in Materials and Methods (21) . As shown in Figure 3A , HnRNPA2B1 was bound to RNA for Bcl-2, Bax, Bcl-X and Bak rather than with Bim. Control immunoprecipitations with anti-actin did not enrich any mRNAs of the Bcl-family. These results suggest that HnRNPA2B1 may participate in RNA posttranscriptional modification for Bcl-family genes.
To date, the cellular function of HnRNPA2B1 in RNA splicing has not yet been reported. Since HnRNPA2B1 binds to the mRNA of the Bcl-family, we investigated whether intracellular concentration changes of HnRNPA2B1 could modulate the alternative splicing of the Bcl-family. As shown in Figure 3B Sam68 phosphorylation regulates splicing of Bcl-x(L) in pancreatic cancer cells It has been shown that Sam68 regulates alternative splicing of Bcl-x by binding to the mRNA and mediating the posttranscriptional modification of this mRNA in HEK293 cells (12) . Therefore, we investigated whether the activation of Fyn also modulated Sam68 phosphorylation and regulated the alternative splicing of Bcl-x in pancreatic cancer cells. As shown in Figure 4 , the expression of Sam68 did not change in BxPc3KD-Fyn, BxPc3GFP and BxPc3 cells ( Figure 4A, panels 1) . However, the phosphorylation of Sam68 decreased ( Figure 4B, top panel, lane 1 versus 2, 3) , whereas the binding HnRNPA2B1 and Sam68 synergistically regulate the apoptosis of pancreatic cancer cells To determine the roles of HnRNPA2B1 and Sam68 in regulating cell apoptosis, we investigated apoptosis in these pancreatic cancer cells using TUNEL staining. As shown in Figure 5 , there were apoptotic nuclei in ,5% of BxPc3 cells and BxPc3GFP cells but .35% in the BxPc3KD-Fyn cells ( Figure 5, a-c) . Inhibition of HnRNPA2B1 expression by RNAi in BxPc3 cells significantly increased cell apoptosis to 25% ( Figure 5, d) . Moreover, upregulation of HnRNPA2B1 or suppression of Sam68 by RNAi could partially rescue BxPc3KD-Fyn cells from apoptosis ( Figure 5 , e and f). In this case, the apoptotic nuclei numbered ,15%. These results indicate that HnRNPA2B1 and Sam68 synergistically regulate the apoptosis of pancreatic cancer cells.
Discussion
In this study, we found that the expression and activity of Fyn were correlated with metastasis of human pancreatic cancer cells. Inhibition of Fyn activity reduced the expression of HnRNPA2B1. Using multiple experimental approaches, we have shown that HnRNPA2B1 binds to endogenous Bcl-x mRNA and affects the ratio of the proapoptotic Bcl-x(s) mRNA to the anti-apoptotic Bcl-x (L). In addition, deactivation of Fyn decreased the phosphorylation of Sam68 and increased its binding to Bcl-x mRNA, thereby decreasing the formation of anti-apoptotic Bcl-x(L). The results of our study provide new evidence that HnRNPA2B1 is involved in apoptosis via regulation of the pro-apoptotic Bcl-x(s) mRNA. In addition, we suggest a mechanism by which Fyn requires HnRNPA2B1 and Sam68 to coordinate and thereby regulate apoptosis in pancreatic cancer cells.
The Src family of kinases is often upregulated in cancer cells and contributes to cell proliferation and invasion (22) . However, the molecular details of how Fyn signaling is linked to RNA alternative splicing are still unclear (23) . We previously found that Fyn was upregulated in .85% of human pancreatic cancer tissues; this correlated with the metastastic potential of pancreatic cancer (11) . Our in vitro study showed that the activity of Fyn rather than Src was increased in metastatic pancreatic cancer. The inhibition of Fyn activation by KD-Fyn significantly decreases cell proliferation and liver metastasis of pancreatic cancer cells (11) . Further studies showed that suppression of Fyn activity by KD-Fyn significantly changed spliced Bcl-x isoforms, with a decrease in anti-apoptotic Bcl-x(L) and an increase in pro-apoptotic Bcl-x(s) ( Figure 3B, lane 2) , and thus promoted apoptosis of pancreatic cancer cells. These results indicate that the activation of Fyn protects pancreatic cancer cells from apoptosis via regulating Bcl-x splicing and thereby promotes the proliferation and metastasis of pancreatic cancer cells.
HnRNPA2B1 is an RNA-binding protein that regulates cell cycle progression (18) . However, there is no direct evidence to show that HnRNPA2B1 participates in RNA modification. In this study, we found a new function of HnRNPA2B1; its participation in RNA processing of Bcl-x. Firstly, using proteomic analysis, we found that the Fyn-HnRNPA2B1/Sam68 and pancreatic cancer cancer cells from apoptosis in BxPc3KD-Fyn cells. These results indicate that HnRNPA2B1 is an important splicing factor for regulating the formation of Bcl-x(s) and participating in the regulation of cell apoptosis. In addition, the expression level of HnRNPA2B1 correlates with human pancreatic cancer progression. Therefore, activation of Fyn protects pancreatic cancer cells from apoptosis by upregulating HnRNPA2B1 expression and thus promoting pancreatic cancer progression.
Previous work has shown that activation of Src affects Bcl-x splicing via tyrosine phosphorylation of Sam68 (14) . In this study, we found that Sam68 participates in Fyn signaling to regulate cell apoptosis in pancreatic cancer cells. Firstly, in BxPc3 cells, KD-Fyn transfection significantly reduced the phosphorylation of Sam68 (Figure 4B top panel) but increased the binding of Sam68 to Bcl-x mRNA ( Figure  4B bottom panel) , thus resulted in the formation of more anti-apoptotic Bcl-xL ( Figure 4C, lane 4) . Secondly, downregulation of Sam68 by RNAi in BxPc3 cells or in BxPc3KD-Fyn cells resulted in an increase in BcL-x(L) isoforms ( Figure 4C top panel, lanes 5, 6 versus 2, 3) . As another RNA-binding protein, HnRNPA1 is known to compete with ASF/SF2 and promotes the formation of the BcL-x(L) isoforms. In this study, we found that HnRNPA1 formed a complex with Sam68 in BxPc3KD-Fyn cells rather than in BxPc3 cells (Zhi-Yu Chen, Lei Cai, Jin Zhu, Min Chen, Jian Chen, Zhi-Hua Li, Xiang-De Liu, ShuGuang Wang, Ping Bie, Peng Jiang, Jia-Hong Dong and Xiao-Wu Li, unpublished observations). These results are consistent with previous reports (14, 24) , which demonstrate that activation of Fyn promotes Sam68 phosphorylation. This results in less inhibition of HnRNPA1 by Sam68 and thereby results in the formation of more Bcl-x(L) isoforms.
In conclusion, our results provide a possible explanation for how the Fyn-A2B1/Sam68-signaling pathway regulates apoptosis of pancreatic cancer cells ( Figure 5B ). In pancreatic cancer, Fyn is activated via two pathways that regulate apoptosis: one is by the upregulation of HnRNPA2B1 expression, which reduces the formation of proapoptotic Bcl-x(s) isoforms; the second is the tyrosine phosphorylation of Sam68, which results in less inhibition of HnRNPA1 by Sam68 and promotes formation of anti-apoptotic Bcl-x(L) mRNA. Thus, by changing Bcl-x splicing, the Fyn-HnRNPA2B1/Sam68-signaling pathway can modulate the survival of pancreatic cancer cells and thereby influence the proliferation and metastasis of pancreatic cancer.
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